文献速递糖尿病

钠-葡萄糖协同转运蛋白2抑制剂使用与癫痫的关联:基于目标试验模拟的人群研究

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors and Epilepsy: A Population-Based Study Using Target Trial Emulation.
PubMed 文献 · Diabetes Care · 2025-01-01

本研究基于鄞州区域医疗数据库模拟目标试验,比较2型糖尿病新使用SGLT-2i与DPP-4i者,最终队列含SGLT-2i新用户24,930例与DPP-4i起始者28,924例。中位随访2.0年期间发现243例新发癫痫,SGLT-2i使用与癫痫发生率降低相关,HR为0.71(95%CI 0.52-0.97)。

要点

  • 中位随访2.0年,SGLT-2i组癫痫发生率为174.2/10万人年,DPP-4i组为231.5/10万人年。
  • 经IPTW控制混杂后,SGLT-2i使用与癫痫发生率降低相关,HR 0.71(95%CI 0.52-0.97)。
  • 亚组分析与敏感性分析支持主要分析结果,但作者指出需更多研究确认和重复该结果。

核心结论

  • 在研究人群中,SGLT-2i使用与癫痫发生率降低相关。
  • 作者指出需要更多研究来确认和重复该研究结果。

研究设计与样本

  • 基于鄞州区域医疗数据库模拟目标试验,比较SGLT-2i与DPP-4i。
  • 组建2型糖尿病中SGLT-2i或DPP-4i新使用者的队列。
  • 最终队列包括SGLT-2i新用户24,930例和DPP-4i起始者28,924例。
  • 采用逆概率治疗加权(IPTW)和Cox比例风险回归模型估计HR和95%CI。

主要发现

  • 中位随访2.0年(四分位距0.8-3.3年)期间共发现243例新发癫痫患者。
  • SGLT-2i使用者癫痫发生率为174.2/10万人年,DPP-4i使用者为231.5/10万人年。
  • 经IPTW控制潜在混杂后,SGLT-2i使用与癫痫发生率降低相关,HR为0.71(95%CI 0.52-0.97)。
  • 各种亚组分析和敏感性分析支持主要分析结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要更多研究来确认和重复该研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Preclinical studies in animals have suggested potential neuroprotective effects of sodium-glucose cotransporter 2 inhibitors (SGLT-2is), but no epidemiological study has investigated the potential effects of SGLT-2is on epilepsy risk. We aimed to assess the association between use of SGLT-2is and epilepsy incidence. RESEARCH DESIGN AND METHODS: We emulated a target trial comparing SGLT-2is and dipeptidyl peptidase 4 inhibitors (DPP-4is) based on the Yinzhou Regional Health Care Database. Cohorts of patients with type 2 diabetes mellitus who were new users of an SGLT-2i or a DPP-4i were assembled. Inverse probability of treatment weighting (IPTW) and Cox proportional hazards regression modeling were applied to estimate the hazard ratio (HR) and 95% CI of the association between use of SGLT-2is and incidence of epilepsy. RESULTS: The final cohort included 24,930 new users of SGLT-2is and 28,924 initiators of DPP-4is. A total of 243 patients with incident epilepsy were found during a median follow-up of 2.0 (interquartile range 0.8-3.3) years, with the incidence of epilepsy being 174.2 and 231.5 per 100,000 person-years in users of SGLT-2is and DPP-4is, respectively. After controlling for potential confounding using IPTW, SGLT-2i use was associated with a lower incidence of epilepsy, with an HR of 0.71 (95% CI 0.52-0.97). Various subgroup analyses and sensitivity analyses supported the results in primary analyses. CONCLUSIONS: SGLT-2is were associated with a reduced incidence of epilepsy in the study population. More studies are needed to confirm and replicate the study results.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Zhao H, Zhang B, Zhuo L, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors and Epilepsy: A Population-Based Study Using Target Trial Emulation. Diabetes Care. 2025. PMID: 40131448. doi:10.2337/dc24-2532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。